Clinical Trials Browser

Phase 3 × Withdrawn × Gynecologic × Clear all

Uterine Cervical Neoplasms

NCT05712941 2023-11-03

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Phase 3 Withdrawn

Gynecologic

Endometrial Neoplasms

NCT04943627 2022-10-05

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT02201381 2022-07-18

METRICS

Phase 3 Withdrawn

BreastCNSGastrointestinalGynecologic

Brain Neoplasms, Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT04806945 2022-05-05

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

NCT03806049 2021-07-15

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Phase 3 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT00693342 2020-02-24

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

Phase 3 Withdrawn

Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT00531349 2016-05-09

ECA/R

Phase 3 Withdrawn

Gynecologic

Agnosia, Neoplasms, Endometrial Neoplasms

NCT02392676 2016-05-02

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Phase 3 Withdrawn

Gynecologic

Ovarian Neoplasms

NCT01492920 2014-12-31

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

Phase 3 Withdrawn

Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Fatigue, Ovarian Neoplasms, Pain, Neurotoxicity Syndromes

NCT00057928 2012-06-13

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 3 Withdrawn

Gynecologic

Uterine Cervical Neoplasms

Clinical Trials

Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer

Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer

Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)

METRICS

A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission

ECA/R

Olaparib Maintenance Treatment Versus Placebo in Patients With PSR Ovarian Cancer Who Are in CR or PR to Platinum-based Chemotherapy and Whose Tumours Carry sBRCAm or HRR-associated Genes Mutations

Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer Undergoing Chemotherapy

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer